EyePoint Pharmaceuticals, Inc. Logo

EyePoint Pharmaceuticals, Inc.

Develops sustained drug delivery therapeutics for serious retinal diseases.

EYPT | US

Overview

Corporate Details

ISIN(s):
US74440J1016 (+1 more)
LEI:
Country:
United States of America
Address:
480 PLEASANT STREET, 2472 WATERTOWN

Description

EyePoint Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for serious retinal diseases. The company leverages its proprietary Durasert E™ technology, a bio-erodible platform for sustained intraocular drug delivery, to create durable therapies. Its lead investigational product, DURAVYU™ (EYP-1901), combines the tyrosine kinase inhibitor vorolanib with the Durasert E™ system for the potential treatment of VEGF-mediated retinal diseases. The company's goal is to improve patient outcomes and reduce treatment burden by providing long-lasting treatments for chronic eye conditions.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all EyePoint Pharmaceuticals, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for EyePoint Pharmaceuticals, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for EyePoint Pharmaceuticals, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

BRISTOL MYERS SQUIBB CO Logo
A global biopharmaceutical company that discovers, develops, and commercializes medicines.
United States of America
BMY
An R&D-focused company developing drugs for CNS disorders and oncology.
South Korea
003000
C4 Therapeutics, Inc. Logo
Clinical-stage biopharma developing targeted protein degradation therapeutics.
United States of America
CCCC
Cadrenal Therapeutics, Inc. Logo
A late-stage biopharmaceutical company developing novel anticoagulation therapeutics.
United States of America
CVKD
CalciMedica, Inc. Logo
Develops CRAC channel inhibitors for acute inflammatory and immunologic diseases.
United States of America
CALC
Calidi Biotherapeutics, Inc. Logo
Develops stem cell platforms to deliver oncolytic viruses for cancer therapy.
United States of America
CLDI
Calliditas Therapeutics Logo
Biopharma company developing and commercializing treatments for rare diseases.
Sweden
CALTX
CALTH. Inc Logo
Develops in vitro diagnostic tools for point-of-care and self-testing.
South Korea
402420
Cambrex Logo
A CDMO providing drug substance, drug product, and analytical services.
United States of America
CBM
CAMBRIDGE NUTRITIONAL SCIENCES PLC Logo
Develops and manufactures diagnostic tests for food sensitivity and gut health.
United Kingdom
CNSL

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.